CARLSBAD, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the issuance of its United States Patent No: 11,832,853 entitled "Hybrid Radiolucent Surgical Operating Tube".

Aurora Spine's Ghost Tube was designed to provide superior anchoring with a translucent thermoplastic body and non-slipping titanium anchors to assure that minimally invasive surgical access will stay stationary to support surgical preparation tools without blocking x-ray visualization during surgery.

"Aurora Spine has created several disruptive technologies in the past 12 years", said Trent Northcutt, President & CEO of Aurora Spine. " This newly received patent of our GhostTube that supports our recently launched SiLO TFX SI Fusion System will allow us to support delivery of the SiLO TFX implant and create several new radiolucent tools for future product lines that require a steady and reliable bone anchoring with a repeatable clinical outcome for each patient requiring joint stabilization surgery."

Laszlo Garamszegi, Chief Technology Officer of Aurora Spine, added "We are very excited to receive another United States patent that bolsters our growing product and intellectual property portfolio. Aurora will continue being disruptive and innovative by looking at ways to efficiently deliver our products and create and improve new treatment options to improve patient care and overall patient outcomes."

About Aurora Spine

Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company's products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.

Contact:

Aurora Spine Corporation

Trent Northcutt
President and Chief Executive Officer
(760) 424-2004

Chad Clouse
Chief Financial Officer
(760) 424-2004